Dr. Dunne shared his expertise on, the integration of ctDNA in treatment decisions for colon cancer patients. Then the conversation lead to the significance of next-generation sequencing (NGS) and biomarker testing, followed by insights into the Code Break 301 trial and its potential impact on standard care for chemorefractory colorectal cancer.
